Key result
COPD in post-MI patients was associated with lower beta-blocker prescription and higher odds of secondary prevention non-use.
Answers are grounded in this paper and cite their sources.
This editorial refers to ‘Beta-blocker, aspirin and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark’, by D.B. Rasmussen et al., doi: 10.1093/ehjqcco/qcy063. There’s pretty good evidence now that people with chronic obstructive pulmonary disease (COPD) are at increased risk of serious cardiovascular (CV) events including myocardial infarction (MI) compared with the general population.1 In fact, COPD per se could arguably be considered a coronary artery disease equivalent (similar to chronic kidney disease), as these patients are more likely to die from cardiovascular disease (CVD) than from a respiratory cause.2 Whether the increased propensity to CVD is due to shared common risk factors, overspill from the airways and enhanced systemic inflammation from COPD really doesn’t matter.3,4 What does matter, is that despite the consistent evidence that COPD patients are at greater risk of and have greater mortality after an MI compared with those without COPD, which they have a delay in diagnosis of ST elevation myocardial infarction (STEMI) and Non ST elevation myocardial infarction (NSTEMI) and that they are less likely to be prescribed secondary prevention medications following an MI, clinical practice doesn’t seem to change.5,6 Even with COPD specifically mentioned in cardiac guidelines: ‘Beta-blockers are only relatively contraindicated in asthma, but not in COPD….’ COPD patients are still less likely to be prescribed beta blockers than those without COPD. In this study by Rasmussen et al.,7 data from the Danish national registers were used to identify patients who have had an MI, and who also may or may not have COPD. Such as other studies of this type, they found a difference in the proportion of people receiving a beta blocker after an MI depending upon whether they had COPD or not: 53% vs. 76%. Those COPD patients most likely to be prescribed a beta blocker were more likely to be male, younger and have cardiovascular risk factors such as hypertension, diabetes, peripheral vascular disease, and renal failure. And, yet, those COPD patients with frequent exacerbations, the ones with heightened risk of recurrent CV events and death, were far less likely to be prescribed a beta blocker. The investigators also point out that albeit improvement in the utilization of medications for secondary prevention over time, COPD continued to be a significant predictor of non-use (odds ratio for non-use 1.86, 95% confidence interval 1.76–1.97). What’s even more puzzling perhaps, and this isn’t the first study to report it, is the underutilization of statins and aspirin among the COPD population post-MI too.8 So why the reluctance to prescribe beta blockers to people with COPD? We suspect the answer is multifactorial. First, one needs to get the diagnosis of COPD correct. We know there is misclassification between asthma and COPD and an inherent fear of getting the diagnosis wrong undoubtedly is a factor. Second, concern over reducing baseline Forced expiratory volume (FEV1) in a COPD patient which may impact on their symptoms. Finally, there is concern among clinicians that beta blockers may diminish response to beta agonists rendering their long-term benefits less impactful. The evidence for the harmful effects of beta-blockers in COPD is limited to certain small retrospective studies.9,10 Antithetically, large retrospective studies show that beta blockers reduce severe COPD exacerbations with trends towards reduction in mortality11,12; possibly related to the beneficial effect of treating undiagnosed CVD. Similarly, a large meta-analysis of randomized clinical trials reveal that the use of cardio selective beta blockers does not change FEV1 vs. placebo. Furthermore, FEV1 treatment response to beta2-agonists was unaltered by prolonged cardio selective beta blockade.13 Despite lack of clear evidence, beta blockers, proven to reduce CV events and mortality in patients with CVD, are often avoided due to an apparent risk of bronchoconstriction. Indeed, there are several editorials and reviews in respiratory journals highlighting the benefits and the need to prescribe beta blockers in COPD patients with CVD.14 The lack of prescription of aspirin and statins is perhaps more puzzling. While there has been debate around the benefit of aspirin and statins in the COPD population with respect to primary prevention, their role in the secondary prevention of CV events has been established beyond reasonable doubt.15 What will it take to change clinical practice? Well, perhaps we need to start to communicate with each other instead of publishing in our own journals. It is simply not enough to send out a new set of respiratory guidelines to cardiologists and vice versa and expect there to be a change in clinical practice. This paper and inviting a respiratory physician with a research interest in CVD in people with COPD to write an editorial accompanying it are first steps. Ultimately, what this requires is an evolutionary team approach consisting of respiratory physicians and cardiologists working together instead of in our silos to make life better for our COPD patients with CVD. Conflict of interest: none declared. The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal – Quality of Care and Clinical Outcomes or of the European Society of Cardiology.
No takes yet. Share an insight, caveat, or question.
Sundaram et al. (2019) conducted an editorial in First-time myocardial infarction and chronic obstructive pulmonary disease (COPD). Chronic obstructive pulmonary disease (COPD) vs. No COPD was evaluated on Beta-blocker prescription/non-use after myocardial infarction (OR 1.86, 95% CI 1.76-1.97). COPD in post-MI patients was associated with lower beta-blocker prescription and higher odds of secondary prevention non-use.
Synapse has enriched 10 related papers. Consider them for comparative context: